https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/cannabidiol-trial-shows-reduction-seizures-children-dravet-syndrome/
Cannabidiol trial shows reduction in seizures for children with Dravet syndrome
30 May 2017, 12:58 p.m.
A trial conducted in Europe and the USA has shown that cannabidiol – a drug derived from cannabis but with the psycho-active elements removed – reduces seizures in children with a form of drug resistant epilepsy, known as Dravet syndrome.
The study was led by NIHR GOSH BRC cross cutting theme lead Professor Helen Cross, in collaboration with New York University.
In the trial one hundred and twenty children with Dravet syndrome across Europe and the USA were given two daily doses of cannabidiol orally for fourteen weeks. At the end of the study the average number of severe seizures reduced by nearly 40%. For 5% of patients, seizures stopped completely.
The research, Trial of Cannabidiol for Drug-Resistant seizures in the Dravet Syndrome, was published in the New England Journal of Medicine.
Read the press release.
Research internships: building a more inclusive pipeline into clinical academia
Through our Research Hospital Internship programme, the NIHR GOSH Biomedical Research Centre (BRC) is enabling healthcare professionals from diverse backgrounds to take their first steps into research.
Working together to transform research
Our Highlight Report shines a spotlight on some of our brightest and best work in 2025-26. Our Impact report brings together a series of case studies and reflections that showcase the breadth and depth of PPIE across our organisation.
UK-wide excellence in paediatrics
Through the Paediatric Excellence Initiative, the NIHR GOSH Biomedical Research Centre is building a connected, collaborative UK-wide system to accelerate paediatric research.
Researchers identify brain network linked to deadliest childhood brain cancer
Researchers at GOSH and University College London have identified a human brain network associated with survival in children with diffuse midline glioma, the deadliest childhood brain cancer.